MiR-1 suppresses proliferation of osteosarcoma cells by up-regulating p21 via PAX3

Cancer Genomics and Proteomics

Volumn 16, Issue 1, 2019, Pages 71-79

  Fujii, Ryota ^a   Osaka, Eiji ^a   Sato, Kentaro ^a   Tokuhashi, Yasuaki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MiR 1; Osteosarcoma; P21; p53 independent pathway; PAX3

Indexed keywords

MICRORNA 1; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR PAX3; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA; MIRN1 MICRORNA, HUMAN; PAX3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PERITUMORAL DRUG ADMINISTRATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; APOPTOSIS; BONE TUMOR; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OSTEOSARCOMA; PAX3 TRANSCRIPTION FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85059122682     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: 10.21873/cgp.20113     Document Type: Article

References (29)

1. Uribe-Botero G, Russell WO, Sutow WW and Martin RG: Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 67(5): 427-435, 1977.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20(3): 776-790, 2002.
3. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A and Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23(3): 559-568, 2005.
4. Szuhai K, Cleton-Jansen AM, Hogendoorn PC and Bovee JV: Molecular pathology and its diagnostic use in bone tumors. Cancer Genet 205(5): 193-204, 2012.
5. Di Leva G, Garofalo M, Croce CM: MicroRNAs in cancer. Annu Rev Pathol 9: 287-314, 2014.
6. Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 34(4): 2093-2098, 2013.
7. Tutar L, Tutar E, Ozgur A and Tutar Y: Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. Drug Dev Res 76(7): 382-388, 2015.
8. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D and Wang D: Functional elucidation of miR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388(1): 35-40, 2009.
9. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O and Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46): 4065-4074, 2009.
10. Bahador R, Taheriazam A, Mirghasemi A, Torkaman A, Shakeri M, Yahaghi E and Goudarzi PK: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults' age groups and their association with prediction of poor prognosis in human osteosarcoma. Tumour Biol 37(3): 3091-3095, 2016.
11. Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 42(2): 667-675, 2013.
12. Townley-Tilson WH, Callis TE and Wang D: MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42(8): 1252-1255, 2010.
13. Nohata N, Hanazawa T, Enokida H and Seki N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3(1): 9-21, 2012.
14. Han C, Yu Z, Duan Z and Kan Q: Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int 2014: 428371, 2014.
15. Tominaga E, Yuasa K, Shimazaki S and Hijikata T: MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res 319(3): 77-88, 2013.
16. Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, Hornicek FJ and Duan Z: MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res 32(8): 1075-1082, 2014.
17. Li L, Sarver AL, Alamgir S and Subramanian S: Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 92(4): 571-583, 2012.
18. Jiang C, Chen H, Shao L and Wang Q: MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31. Oncol Rep 32(3): 1249-1256, 2014.
19. Niu J, Sun Y, Guo Q, Niu D and Liu B: miR-1 inhibits cell growth, migration, and invasion by targeting VEGFA in osteosarcoma cells. Dis Markers 2016: 7068986, 2016.
20. Chi N and Epstein JA: Getting your Pax straight: Pax proteins in development and disease. Trends Genet 18(1): 41-47, 2002.
21. Fang WH, Wang Q, Li HM, Ahmed M, Kumar P and Kumar S: PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways. J Cell Mol Med 18(1): 38-48, 2014.
22. Liu Q, Yang G and Qian Y: Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway. Mol Carcinog 56(4): 1312-1321, 2017.
23. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283(48): 33394-33405, 2008.
24. Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, Tang K, Zhou H, Huang Q, Li A, Li Y, Ye Z, Wang J and Xu H: MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget 6(15): 13201-13215, 2015.
25. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K and Jacob ST: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68(13): 5049-5058, 2008.
26. Jiang S, Zhao C, Yang X, Li X, Pan Q, Huang H, Wen X, Shan H, Li Q, Du Y and Zhao Y: miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. Int J Mol Med 38(1): 113-122, 2016.
27. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, et al.: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10(11): 5772-5781, 1990.
28. Rao-Bindal K and Kleinerman ES: Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma 2011: 679457, 2011.
29. Chen J, Xia L, Wu X, Xu L, Nie D, Shi J, Xu X, Ni L, Ju S, Zhu H and Shi W: Clinical significance and prognostic value of PAX3 expression in human glioma. J Mol Neurosci 47(1): 52-58, 2012.